VIATRIS INC. for VIATRIS INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 20, 2015 | $390,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Apr 20, 2016 | $440,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act (GDUFA)
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NIMISH SHAH | — |
Trade (domestic/foreign) TRD
Trans Pacific Partnership(TPP), General trade issues
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NAWEL LILLIAN ROJKJAER | — |
| NIMISH SHAH | — |
Taxation/Internal Revenue Code TAX
Corporate Tax Reform, Proposals to reform domestic and international tax structures
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NIMISH SHAH | — |
Copyright/Patent/Trademark CPT
Patent Reform, H.R. 9 Innovation Act, S. 632 STRONG Patents Act, S. 2019 Preserve Access to Affordable Generics Act Access for Generics to Inter Partes Review (IPR)
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NIMISH SHAH | — |
Health Issues HCR
Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act (GDUFA) Prescription drug pricing, Medicare Part D program and Generic Drugs HR 6 21st Century Cures Act; Innovation for Healthier Americans Initiative; Issues regarding market exclusivity Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, H.R. 2841 FAST generics Act S. 1972 Airline Access to Emergency Epinephrine Act of 2015, Anaphylaxis awareness, access to epinephrine auto injector Issues related to the antitrust review of Teva Pharmaceuticals Industries, Ltd. offer to acquire Mylan N.V.
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NIMISH SHAH | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| MYLAN HOLDINGS LIMITED | United Kingdom | United Kingdom | 100.0% | — |
| MYLAN NV | United Kingdom | United Kingdom | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.